5-Hydroxymethylcytosine (5hmC) at or near cancer mutation hot spots as potential targets for early cancer detection

Michael J. Lu and Yabin Lu*

Abstract

Objective: Universal noninvasive genomic screening to detect cancer and/or fetal DNA in plasma at all stages of development is highly warranted. Since 5-hydroxymethylcytosine (5hmC) emerged as an intermediate metabolite in active DNA demethylation, there have been increasing efforts to elucidate its function as a stable modification of the genome. In the current study, we demonstrate that discrete 5hmC sites within 80 bp hotspot regions exist in a greater proportion of cancer versus normal cells.

Result: 5hmC was detected in 16 of 17 known hotspots having C to T or G to A mutations. The results show the presence of two characteristically distinct 5hmC groups: Tier 1 Group with 3 to eightfold more 5hmCs detected in tumor-cells than in normal-cell derived DNA (as observed in 6 of 11 CpG sites). Tier 2 group with equal allele frequency of 5hmC among normal and tumor-cell derived DNA at 5 CpG hotspot sites as well as 5 non-CpG hotspots. Thus, detection and quantification of the Tier 1 group of 5hmC sites or its prevalence at or near cancer mutation hot spots in cells may enable early detection, screening and potentially prediction of the likelihood of cancer occurrence or the severity of the cancer.

Keywords: 5hmC, Cancer hotspots, DNA methylation

Introduction

Noninvasive methods for detection of cancer or fetal DNA in plasma include DNA methylation. DNA methylation, at the 5-position of cytosine to form 5-methylcytosine (5-mC), which occurs predominantly in the context of CpG dinucleotides, is one of the best-characterized epigenetic modifications in processes [1, 2].

In 2009, two reports in Science indicated that mammalian genomic DNA contains not only 5-mC but also 5-hydroxymethylation (5hmC), which is now widely regarded as the “sixth base” in the mammalian genome [3, 4]. In one well-known mechanism, 5hmC is produced from 5mC in an enzymatic pathway involving three 5mC oxidases, Ten-eleven translocation (TET)1, TET2, and TET3. Formation of 5hmC from 5mC lowers the levels of 5mC genome wide. It was speculated that the conversion of 5mC into 5hmC could be the first step or precursor to a pathway leading towards DNA demethylation [5]. However, the biological role of 5hmC remains unclear.

To date, no studies have examined 5hmC directly at base-resolutions within any gene coding region, especially regions surrounding known mutation hotspots known to play active roles in cancer development. In this study, we use chemical oxidation and reduction technique combined with Next Generation Sequencing (NGS) to investigate the novel existence of 5hmC on CpG sites located at and around mutation hotspots. We demonstrate an association of increased quantity of 5hmC within hotspots in cancer/tumor-derived cells but not normal cells. These findings suggest 5hmC as a novel marker and potential precursor to mutation at cytosine

*Correspondence: yabin.lu@anchormolecular.com
Anchor Molecular Inc., New York, USA
and thus means for distinguishing abnormal cancer cells from normal cells.

**Main text**

**Materials and methods**

**Source of DNA**

In the first study, normal cell DNA is extracted from one patient's peripheral blood mononuclear cells (PBMCs) purchased from iXCells Biotechnologies. Two cell lines were used to represent tumor cells, PAM3005 and HCT116. PAM3005 cells are fibroblasts transformed by SV40 T antigen. It harbors both BRCA1 p.P871L and BRCA2 p.N372H heterozygous mutations. HCT116 cells are colon cancer derived and obtained as a gift from Max-Planck-Innovation GmbH. In the second study, genomic DNAs extracted from three pairs of matched colon cancer and normal tissue were purchased from Biochain Institute.

**Genomic DNA preparation in the first study**

Extraction and gDNA digestion were performed following the method by Brand M, et al. [6]. Frozen cells were thawed on ice before washing twice with PBS followed by two washes with Buffer N. The cells were resuspended in Lysis Buffer containing 0.3% NP40. Lysed cells were centrifuged at 524 × g in a tabletop centrifuge for 5 min to collect the nuclei. Nuclei were resuspended with Buffer N. After determining the gDNA concentration, MNase was added to the suspension at 1.25 mU per µg of DNA for 10 min incubation at 37 °C. The reaction was stopped with MNase Stop Buffer. The fragmented gDNA was treated with Proteinase K followed by purification with Phenyl:Chloroform extraction and ethanol precipitation.

**5hmC oxidation**

We followed the 5hmC oxidation procedure described by Liu et al. [7]. Briefly, 5hmC DNA oligonucleotide (46 µl) was denatured with 2.5 µl of 1 M NaOH for 30 min at 37 °C in a shaking incubator, then oxidized with 1.5 µl of solution containing 50 mM NaOH and 15 mM potassium perruthenate (KRUO4, Sigma-Aldrich) for 1 h on ice. The product was purified using Micro Bio-Spin 6 Columns following the manufacturer’s instructions.

**Pyridine Borane reduction**

As described by Liu et al. [7], oxidized DNA (50–100 ng) in 35 µl of water was reduced in a 50 µl reaction containing 600 mM sodium acetate solution (pH 4.3) and 1 M pyridine borane for 16 h at 37 °C and 850 rpm in an Eppendorf ThermoMixer. The product was purified using Zymo-Spin columns.

**NGS**

Genomic DNA (gDNA) was treated with KRUO4 followed by Borane to convert the 5hmC to uracil (T). An amplicon-based NGS panel was designed to sequence 50 variant targets, 33 of which are single nucleotide variant (SNV). In the first study, we examined 17 of the 33 SNV targets with 80 bp regions centered around either C or G base at each hotspot. In the second study, 80 bp regions of all 33 SNV were examined.

**Results**

**Identification of two groups of 5hmC at Hotspots**

In the first study, we examined the presence of 5hmC at 17 hotspots and their flanking regions (around 80 bp with hotspot at center). The 17 hotspots were the only C- or G-containing targets in our NGS panel targeting 33 most popular SNVs. 11 of the 17 hotspots have CpG sites located right at the hotspot location. Genomic DNA (gDNA) was treated with KRUO4 followed by Borane to convert the 5hmC to uracil (T). The 80 bp regions of each hotspot were sequenced by NGS. The differences in allele frequency (AF) of 5hmC between cfDNA fragments from normal and cancer cells were compared.

Allele frequencies of 5hmC at each hotspot are shown in Table 1. DNAs from normal cells (PBMC) and the two cancerous/tumor cells were compared. Both base C and G of the CpG were examined. Those AFs higher than 8% were highlighted as red and those between 4 and 8% were highlighted as orange. In cancerous cells, most CpG hotspot sites have both the C and G in the CpG island mutated.

Two groups with similar characteristics were observed: (1) Tier 1 (top half of Table 1): with significantly more 5hmCs detected in cancerous cell gDNA than in normal gDNA (as seen in 6 of the 11 CpG sites and 1 CC site (KRAS G12C)); (2) Tier 2 (bottom half of Table 1): with roughly equal allele frequency of 5hmC detected among normal and cancerous cell DNA in 5 CpG hotspot sites and 5 non-CpG hotspots. Averaged AF for each group, before or after the 5hmC-to-T conversion, were plotted in Fig. 1. Significantly higher 5hmC AF were observed in both PAM3005 and HCT116 in Tier 1, while the AF were comparable among Tier 2. Background level of C > T/G > A for all groups was comparable.

Normal and cancer cells have similar number of 5hmC, most of which are shared with comparable allele frequencies (Tier 2 5hmC sites)

Not just at hotspots, 5hmCs were detected in about a quarter of the total CpG sites within the seventeen 80 bp regions centered around genomic hotspots. There are a total of 726 C or G associated with the CpG sites around the 17 hotspots in the first study. The number of 5hmC
Table 1  Detailed AF% of detected 5hmC at 17 Hotspots (Top: Tier 1; Bottom: Tier 2)

| Chromosome | Tier 1 Hotspot Location | Mutation name | Hotspot Mutation | Bases at hotspot | C of CpG Normal (PBMC) | G of CpG Normal (PBMC) | C of CpG Immortalized (PAM3005) | G of CpG Immortalized (PAM3005) | C of CpG Cancer (HCT116) | G of CpG Cancer (HCT116) |
|------------|-------------------------|---------------|------------------|------------------|-----------------------|----------------------|-----------------------------|-----------------------------|---------------------------|---------------------------|
| chr11      | 108247071               | ATM R337C, c.1009C>T | C>T               | CpG              | 2.1%                  | 56.8%                | 0.7%                        | 8.1%                        |
| chr19      | 11021837                | SMARCA4 T910M, c.2729C>T | C>T               | CpG              | 0.7%                  | 6.1%                 | 1.1%                        | 2.2%                        |
| chr2       | 208248388               | IDH1 R132H, c.395G>A | C>T               | CpG              | 1.4%                  | 2.0%                 | 9.1%                        | 2.8%                        |
| chr1       | 162776212               | DDR2 R709, c.2125C>T | C>T               | CpG              | 7.1%                  | 0.3%                 | 8.9%                        | 9.6%                        |
| chr17      | 39711955                | ERBB2 S310F, c.929C>T | C>T               | CpG              | 3.8%                  | 12.5%                | 16.6%                       | 7.4%                        |
| chr2       | 211623993               | ERBB4 R711C, c.2131C>T | G>A               | CpG              | 1.3%                  | 8.5%                 | 25.3%                       | 9.9%                        |
| chr12      | 25245350                | KRAS G12C, c.34G>T | C>A               | CC               | 22.58%                | 32.14%               |                             |                             |
| chr17      | 7673802                 | TP53 R273H, c.818G>A | C>T               | CpG              | 1.2%                  | 4.1%                 | 2.5%                        | 4.8%                        |
| chr17      | 7674220                 | TP53 R248Q, c.743G>A | C>T               | CpG              | 5.8%                  | 0.6%                 | 8.7%                        | 0.4%                        |
| chr7       | 55181378                | EGFR T790M, c.2369C>T | C>T               | CpG              | 7.4%                  | 4.8%                 | 6.4%                        | 6.0%                        |
| chr17      | 7675088                 | TP53 R175H, c.524G>A | C>T               | CpG              | 2.3%                  | 4.8%                 | 0.8%                        | 6.3%                        |
| chr5       | 112839941               | APC R1450, c.4348C>T | G>A               | CpG              | 6.3%                  | 6.7%                 |                             | 18.6%                       |
| chr15      | 66436824                | MAP2K1 P124S, c.370C>T | C>T               | CC               | 7.2%                  | 5.7%                 |                             | 3.8%                        |
| chr14      | 104780214               | AKTI E17K, c.49G>A | C>T               | CC               | 2.8%                  | 1.9%                 |                             | 4.7%                        |
| chr3       | 41224646                | CTNNB1 S45F, c.134C>T | C>T               | TCT              | 2.1%                  | 1.5%                 |                             | 1.0%                        |
| chr3       | 179218303               | PIK3CA E545K, c.1633G>A | G>A               | TGA              | 2.6%                  | 4.2%                 |                             | 5.4%                        |
| chrX       | 71119404                | MED12 G44D, c.131G>A | G>A               | GG               | 5.1%                  | 5.4%                 |                             | 5.9%                        |
detected were 171, 191 and 185 for the normal PBMS cell, the immortalized PAM3005 and the colon cancer tumor cell HCT116, respectively. 158 of the 5hmC sites were shared by all 3 cell types. Most of the 5hmC sites are Tier 2 which showed comparable AF between gDNA from cancerous and normal cells (Data not shown). Similarly, in the second study using matched tumor-versus-normal DNA, the average number 5hmC sites was 1208 for tumor and 1181 for normal, when AF was above 1%.

Cancerous cells have significantly higher 5hmC at Tier 1 sites at or near hotspots (Tier 1 5hmC sites)

Figure 2 shows a few typical Tier 1 and Tier 2 5hmC. Most of the CpG sites are “5hmC-free”. Tier 1 5hmC are shown both at hotspot (red) or near hotspot (purple). Green arrows indicate the Tier 2 5hmC.

Out of the 726 CpG sites in the first study, we identified 47 Tier 1 sites where cancerous cells exhibited significantly higher AF of 5hmC. Only 3 sites were found to have significantly higher 5hmC in normal cell than from cancerous cells.

In the second study, more 5hmC sites were observed in tumor than normal DNA at higher AF. For example, at 5% AF or above, an average of 606 5hmC sites were found in each tumor DNA versus 442 in normal DNA. At 10%

**Fig. 1** Average Allele Frequency (AF%) of detected C>T (or G>A) at hotspots before and after treatment

**Fig. 2** Tier 1 and Tier 2 Group 5hmcs At or Near Hotspots
or higher, the average number was about 76 in tumor versus 36 in normal. The number of extra 5hmC (Tier 1) found in tumor was proportionally higher in high AF range. Calculated as percentage of 5hmC sites found in normal, there were 2%, 37%, 110%, and 229% more 5hmC counts in tumor, and 22%, 45%, 124% and 255% higher sum of AF values in tumor than in normal gDNA, when detection criteria of AF were set at above 1%, 5%, 10 and 15%, respectively.

The significantly increased 5hmC AF in cancerous/tumor cells implies the potential role of 5hmC in cancer formation and its utility as a cancer marker.

**Discussion**

Efforts in using mutation hotspots as cancer biomarkers have not been fully successful since cancer is usually associated with many mutations. Even the most popular hotspots often do not show up in most cancer cases. Universal markers like methylated cytosine (5-methylcytosine or 5mC) and Tumor Mutation Burden (TMB) have been widely explored as simple markers [8, 9]. However, both markers still lack large-scale validation, precluding implementation in clinical practice [10, 11].

5hmC is a rather common modification of cytosine among all cell types. Majority (80–92%) of these 5hmC are shared, with comparable AF, by both normal and cancerous cells, except the Tier 1 group. The association of increased allele frequency of Tier 1 5hmC to hotspots and its vicinity CpG sites in cancer or transformed cells potentially provides another simple way to distinguish cancer cells from normal cells. Because 5hmC is not detected by normal sequencing techniques as mutated, the increased detection of certain 5hmC groups at hotspots is likely a more sensitive marker of cancerous cells occurring before many mutations (e.g., C to T changes) happened.

Studies on the functional role of 5hmC have been heavily focused on change in chromosome-wide global 5hmC density or concentration, or regulation of transcription in the promoter region, or loss of 5hmC across many types of cancer [12, 13]. Unlike the uniform distribution of 5mC outside of the promoter regions, satellites, and repeat DNA sequences [14], 5hmC has distinct distributions across different functional regions, and its abundance varies across different tissues and cell types [15–17]. Tissue type plays a dominant role in determining the distribution patterns of 5hmC [18]. 5hmC is enriched primarily in the distal regulatory regions, gene bodies of actively expressing genes and promoters, indicating its connection with active transcription [19]. Genome-wide analysis of 5mC has indicated the global hypo-methylation pattern in tumor tissues, whereas depletion of 5hmC has also been associated with the hyper-methylation of gene bodies in various cancers [18, 20, 21]. Significant enrichment of 5hmC is observed in both tissue-specific and cancer-specific differentially methylated regions as compared with that of 5mC [22]. Other discoveries include the findings that several genes coding for proteins involved in the 5mC oxidation reaction are mutated in human tumors and that there is a broad loss of 5hmC across many types of cancer. The disruption of TET2 and IDH1/2 gene function by mutations perturbs 5-hmC levels in hematopoietic stem and progenitor cells and has been shown to participate in the pathogenesis of hematopoietic malignancies. Conflicting results have been reported on inhibition of TET and suppressed hydroxymethylation (5hmC), such as promoting somatic cell reprogramming [23], increased gene expression of tumor suppression [24], and reduced cholangiocarcinoma progression [25].

Moreover, the significant increase of Tier 1 group of 5hmC at many hotspots in cancer cell lines may suggest a previously unknown higher order mechanism underlying the development of hotspot mutation and cancer. 5hmC is a base that is modifiable into uracil (T). Coincidently, many hotspots with the CpG site (6 of the 11 in our case) frequent have both the Cs on both strands mutated to T. It is interesting to investigate the potential role of 5hmC in the formation of C>T hotspot mutations, because, if this hypothesis is true, markers along the 5hmC-mediated mechanism or pathway in cancer development are not only better diagnostic targets than mutations at hotspots, but also potentially better therapeutic targets. Drugs directly or indirectly either prevent 5hmC from occurring, prevent 5hmC from being converted to uracil- or thymine-analog, or correct 5hmC back to regular cytosine may prevent or treat cancer. Our results further support the need for studies to validate the clinical role of 5hmC levels in differentiating normal from tumor cells.

**Limitations**

This work was limited by the number of cells in both the normal and the cancerous cells groups. Further study with increasing number of samples, larger number of hotspots and wider regions flanking the hotspots are needed.

**Abbreviations**

5hmC: 5-Hydroxymethylation; AF: Allele frequency; 5-mC: 5-Methylcytosine; NGS: Next Generation Sequencing.

**Acknowledgements**

We’d like to thank Farideh Bischoff, Ph.D. for her extensive review and assistance in preparing this manuscript.

**Author contributions**

Both authors contributed the conception and design of the work. ML conducted the data collection alone. Both authors contributed to the analysis and
interpretation of the data. Both authors contributed drafting the article. YL was responsible for critical revision of the article and final approval of the version to be published. Both authors read and approved the final manuscript.

Funding
Both authors were not funded by any source.

Availability of data and materials
Materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality. Please contact Dr. Yabin Lu for any data request.

Declarations

Ethics approval and consent to participate
All the samples were legally and ethically obtained, and all the donor information is protected via a de-identification process. We strictly adhere to the guidelines for human tissue collection, cell isolation and distribution in compliance with local, state, and federal laws and regulations (The Declaration of Helsinki).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 20 November 2021   Accepted: 5 April 2022

Published online: 21 April 2022

References
1. Li E, et al. DNA methylation in mammals. Cold Spring Harb Perspect Biol. 2014;6:a019133.
2. Li W, et al. Epigenetic Function of TET Family, 5-Methylcytosine, and 5-Hydroxymethylcytosine in Hematologic Malignancies. Oncol Res Treat. 2019;42:309–17.
3. Kriaucionis S, et al. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009;324:929–30.
4. Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324:930–5.
5. Pfeifer GP, et al. 5-hydroxymethylcytosine in Hematologic Malignancies. Oncol Res Treat. 2014;6:a019133.
6. Brand M, et al. Analysis of epigenetic modifications of chromatin at specific gene loci by native chromatin immunoprecipitation of nucleosomes isolated using hydroxyapatite chromatography. Nat Protoc. 2008;3:398–409.
7. Liu Y, et al. Bisulfite-free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at base resolution. Nature Biotech. 2019;37:424–9.
8. Köhler F, et al. DNA Methylation in Epidermal Differentiation, Aging, and Cancer. J Invest Dermatol. 2020;140:58–47.
9. Sholl LM, et al. The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2020;15:1409–24.
10. Constâncio V, et al. DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types. Cells. 2020;9(3):624.
11. Addeo A, et al. TMB or not TMB as a biomarker. That is the question. Crit Rev Oncol Hematol. 2021;163:103374.
12. Margalit S, et al. 5-Hydroxymethylcytosine as a clinical biomarker. Fluorescence-based assay for high-throughput epigenetic quantification in human tissues. Int J Cancer. 2019;146:115–22.
13. Li W, et al. 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res. 2017;27:1243–57.
14. Song CX, et al. Mapping recently identified nucleotide variants in the genome and transcriptome. Nat Biotechnol. 2012;30:1107–16.
15. Zeng C, et al. Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy. Cancer Commun. 2019;39:12.
16. Yu M, et al. Base-resolution analysis of 5-hydroxymethylcytosine in the mammalian genome. Cell. 2012;149:1368–80.
17. Nestor CE, et al. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genomes. Genome Res. 2012;22:467–77.
18. Thomson JP, et al. The application of genome-wide 5-hydroxymethylcytosine studies in cancer research. Epigenomics. 2017;9:77–91.
19. Han D, et al. A highly sensitive and robust method for genome-wide ShmC profiling of rare cell populations. Mol Cell. 2016;63:711–9.
20. Chen K, et al. Loss of 5-hydroxymethylcytosine is linked to gene body hypermethylation in kidney cancer. Cell Res. 2016;26:103–18.
21. Vasanthakumar A, et al. 5-Hydroxymethylcytosine in cancer: significance in diagnosis and therapy. Cancer Genet. 2015;208:167–77.
22. LIX, et al. Whole-genome analysis of the methylome and hydroxymethylome in normal and malignant lung and liver. Genome Res. 2016;26:1730–41.
23. Singh AK, et al. Selective targeting of TET catalytic domain promotes somatic cell reprogramming. PNAS. 2020;117:3621–6.
24. Gerecke C, et al. Vitamin C in combination with inhibition of mutant IDH1 synergistically activates TET enzymes and epigenetically modulates gene silencing in colon cancer cells. Epigenetics. 2020;15:307–22.
25. Bai X, et al. TET1 promotes malignant progression of cholangiocarcinoma with IDH1 wildtype. Hepatology. 2021;73:1747–17632312.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.